Research Article

HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib

Figure 3

MTT assay in parental HCC827 cells and HCC827 GR cells with different treatments. Cell viability of cells with different treatments (blank control, YC-1, gefitinib, YC-1, and gefitinib combined, for 16 h and 28 h) was evaluated by MTT assay. The concentration of YC-1 was 40 μM, and the final concentration of gefitinib was 20 nM. Error bars represented the (SD). Data were obtained from three independent experiments. and .